Assessment of psychological problems for patients with acute myelogenous leukemia

الملخص EN

Objective: To assess the psychological problems in patients with acute myelogenous leukemia, and to find out the relationship between socio-demographic characteristics such as (age, sex, marital status, educational level, and occupation) and psychological problems for those patients.

Methodology: A descriptive study used the assessment approach from 20th September 2014 to 30th November 2014 in order to study the psychological problems in acute myelogenous leukemia patients with the psychological problems.

Non probability (purposive) sample is selected for the study which includes (50) patients diagnosed with acute myelogenous leukemia were treated at Baghdad teaching hospital and City Imams Kazimain Teaching Hospital or the patients who visited the outpatient clinic in the same hospital for medical follow–up and further treatment.

Data were gathered through the patients` interviewed.

Assessment questionnaire consist of two parts contains demographic characteristic, the other part concerning about assessment the psychological problems for patients with acute myelogenous leukemia.

Reliability and validity of this tool is determined through application of a pilot study and panel of experts.

Data were analyzed through the application of descriptive statistical (frequencies and percentages), inferential statistical (chi square).

Results: The Overall results revealed that the psychological problems in acute myelogenous leukemia patients with psychological problems was unacceptable, and there is significant correlation between the psychological problems related for these patients and was region (residency) of patients.

Conclusions: The study concluded that the majority of the items related to psychological problems for patients with acute myeloid leukemia were low or out of the comparison, reflecting the ferocity of those problems.

Recommendations: The study recommended to increase awareness and psychological education for patients with acute myelogenous leukemia.